ES2788129T8 - Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales - Google Patents

Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales

Info

Publication number
ES2788129T8
ES2788129T8 ES16179214T ES16179214T ES2788129T8 ES 2788129 T8 ES2788129 T8 ES 2788129T8 ES 16179214 T ES16179214 T ES 16179214T ES 16179214 T ES16179214 T ES 16179214T ES 2788129 T8 ES2788129 T8 ES 2788129T8
Authority
ES
Spain
Prior art keywords
tumors
against various
including brain
neuronal
immunotherapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16179214T
Other languages
English (en)
Other versions
ES2788129T3 (es
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Application granted granted Critical
Publication of ES2788129T3 publication Critical patent/ES2788129T3/es
Publication of ES2788129T8 publication Critical patent/ES2788129T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
ES16179214T 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales Active ES2788129T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP08017921.1A EP2172212B1 (en) 2008-10-01 2008-10-13 Novel immunotherapy against several tumors including neuronal and brain tumors
US10592808P 2008-10-16 2008-10-16

Publications (2)

Publication Number Publication Date
ES2788129T3 ES2788129T3 (es) 2020-10-20
ES2788129T8 true ES2788129T8 (es) 2020-11-04

Family

ID=40342382

Family Applications (12)

Application Number Title Priority Date Filing Date
ES08017305.7T Active ES2536465T3 (es) 2008-10-01 2008-10-01 Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
ES08017921.1T Active ES2607460T3 (es) 2008-10-01 2008-10-13 Nueva inmunoterapia contra varios tumores incluidos tumores neuronales y cerebrales
ES16179174T Active ES2804723T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES09778750.1T Active ES2584245T3 (es) 2008-10-01 2009-09-28 Composición que comprende péptidos asociados a tumores y una vacuna para el tratamiento del glioblastoma y de otros tipos de cáncer
ES16179169T Active ES2770090T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16179192T Active ES2819244T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16179226T Active ES2802227T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16165070T Active ES2710608T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16179241T Active ES2708654T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra varios tumores incluyendo tumores cerebrales y neuronales
ES09778749.3T Active ES2612466T3 (es) 2008-10-01 2009-09-28 Composición de péptidos asociados a tumores y vacuna contra el cáncer relacionada con ellos para el tratamiento del glioblastoma (GBM) y de otros tipos de cáncer
ES16179214T Active ES2788129T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16179163T Active ES2802226T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales

Family Applications Before (10)

Application Number Title Priority Date Filing Date
ES08017305.7T Active ES2536465T3 (es) 2008-10-01 2008-10-01 Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
ES08017921.1T Active ES2607460T3 (es) 2008-10-01 2008-10-13 Nueva inmunoterapia contra varios tumores incluidos tumores neuronales y cerebrales
ES16179174T Active ES2804723T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES09778750.1T Active ES2584245T3 (es) 2008-10-01 2009-09-28 Composición que comprende péptidos asociados a tumores y una vacuna para el tratamiento del glioblastoma y de otros tipos de cáncer
ES16179169T Active ES2770090T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16179192T Active ES2819244T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16179226T Active ES2802227T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16165070T Active ES2710608T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
ES16179241T Active ES2708654T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra varios tumores incluyendo tumores cerebrales y neuronales
ES09778749.3T Active ES2612466T3 (es) 2008-10-01 2009-09-28 Composición de péptidos asociados a tumores y vacuna contra el cáncer relacionada con ellos para el tratamiento del glioblastoma (GBM) y de otros tipos de cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16179163T Active ES2802226T3 (es) 2008-10-01 2009-09-28 Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales

Country Status (25)

Country Link
US (19) US8119139B2 (es)
EP (12) EP2172211B1 (es)
JP (10) JP5855940B2 (es)
KR (6) KR102392070B1 (es)
CN (3) CN106986919A (es)
AU (2) AU2009300088B2 (es)
BR (2) BRPI0920791B8 (es)
CA (9) CA2936868C (es)
CY (11) CY1116302T1 (es)
DK (12) DK2172211T3 (es)
EA (3) EA023013B1 (es)
ES (12) ES2536465T3 (es)
HK (2) HK1159526A1 (es)
HR (12) HRP20201025T8 (es)
HU (11) HUE031030T2 (es)
LT (10) LT2172212T (es)
MX (3) MX2011003540A (es)
NZ (4) NZ624533A (es)
PL (12) PL2172211T3 (es)
PT (12) PT2172211E (es)
RS (12) RS53782B1 (es)
SI (12) SI2172211T1 (es)
TR (2) TR201900809T4 (es)
UA (3) UA110599C2 (es)
WO (2) WO2010037514A2 (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
PT2660248E (pt) * 2007-07-27 2015-10-12 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
NO2119726T3 (es) 2008-05-14 2015-05-23
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
MX353165B (es) * 2010-08-24 2017-12-20 Univ Of Pittsburgh Of The Commonwealth System Of Higher Education Star Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
WO2012075490A2 (en) * 2010-12-03 2012-06-07 Duke University Anti-podoplanin antibodies and methods of use
NZ609916A (en) * 2010-12-14 2015-03-27 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2013052158A2 (en) * 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
ES2856091T3 (es) * 2011-09-14 2021-09-27 Univ Northwestern Nanoconjugados capaces de atravesar la barrera hematoencefálica
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
JP2015511936A (ja) * 2012-01-20 2015-04-23 ブラウン、デニス 多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
DK3536334T3 (da) 2012-05-16 2021-09-13 Stemline Therapeutics Inc Cancer stamcelle målrettede cancer vacciner
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
CN110041403B (zh) * 2013-08-05 2023-03-10 伊玛提克斯生物技术有限公司 针对多种肿瘤例如包括nsclc在内的肺癌的新型免疫疗法
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
SG10201809379UA (en) 2014-04-25 2018-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
JP6613526B2 (ja) * 2014-05-28 2019-12-04 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
US10479975B2 (en) 2014-06-06 2019-11-19 Bluebird Bio, Inc. Methods of making T cell compositions
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
CN106795217B (zh) 2014-07-24 2021-08-06 蓝鸟生物公司 Bcma嵌合抗原受体
KR102043725B1 (ko) * 2014-11-06 2019-11-13 오제 이뮈노테라프틱스 뇌 전이 치료를 위한 치료용 다중 펩타이드 t 특이적 면역 요법
SG11201704727WA (en) 2014-12-12 2017-07-28 Bluebird Bio Inc Bcma chimeric antigen receptors
MD3236985T3 (ro) * 2014-12-23 2023-03-31 Immatics Biotechnologies Gmbh Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor tipuri de cancere
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
JP6985153B2 (ja) * 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2016200787A2 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for haemophilus influenzae
MX2017016931A (es) 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20230321A1 (es) 2015-07-01 2023-02-22 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
CA3221001A1 (en) * 2015-07-06 2017-01-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI794761B (zh) 2015-08-28 2023-03-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
WO2017123996A1 (en) 2016-01-15 2017-07-20 City Of Hope Targeting glioblastoma stem cells through the tlx-tet3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
LT3430037T (lt) 2016-03-16 2022-12-12 Immatics Biotechnologies Gmbh Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
BR112018070067A2 (pt) * 2016-04-06 2019-02-12 Immatics Biotechnologies Gmbh peptídeos e combinações de peptídeos para uso em imunoterapia contra lma e outros cânceres
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
ES2950435T3 (es) * 2016-10-03 2023-10-10 Ottawa Hospital Res Inst Composiciones y métodos para mejorar el crecimiento, la propagación y la eficacia oncolítica e inmunoterapéutica de virus oncolíticos de ARN
MX2019005277A (es) 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
AU2017379900A1 (en) * 2016-12-22 2019-06-13 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
SG10201914064QA (en) 2017-01-06 2020-03-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) * 2017-02-28 2018-09-07 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
JP2020518648A (ja) * 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
EP3724327A4 (en) * 2017-12-14 2022-01-12 EZY Biotech LLC SUBJECT-SPECIFIC TUMOR-INHIBITING CELLS AND THEIR USE
WO2019197567A2 (en) * 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
JP2022527629A (ja) 2019-04-05 2022-06-02 アーリー・インコーポレイテッド 合成バイオマーカーのための改良された方法及び組成物
US10937541B2 (en) 2019-05-28 2021-03-02 PAIGE.AI, Inc. Systems and methods for processing images to prepare slides for processed images for digital pathology
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113444149A (zh) * 2020-03-18 2021-09-28 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
MX2022012295A (es) * 2020-03-31 2023-03-06 Walking Fish Therapeutics Celulas b modificadas y metodos de uso de las mismas.
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3190707A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
ES487106A0 (es) 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
EP0942748A4 (en) * 1996-07-22 2004-12-08 Univ Rockefeller ENV-GLYCOPROTEIN VACCINE FOR PROTECTION AGAINST HTLV-I AND HTLV-II INFECTIONS
AU6240798A (en) 1997-01-15 1998-08-07 Zymogenetics Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
JPH11507845A (ja) * 1997-02-13 1999-07-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経細胞付着分子スプライシング変種
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU750358B2 (en) * 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
US20020090672A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055208A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001279581A1 (en) * 2000-09-06 2002-03-22 Friederike Muller Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002226030A1 (en) * 2000-12-04 2002-06-18 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046767A2 (en) * 2000-12-08 2002-06-13 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
WO2004067029A1 (fr) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Procede de preparation d'un vaccin et vaccins antitumoraux
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
US7655751B2 (en) * 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
DE602004019215D1 (de) * 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
US7902143B2 (en) * 2004-12-07 2011-03-08 Toray Industries, Inc. Cancer antigen peptide and the use thereof
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
DK1760089T3 (da) * 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2679743A1 (en) * 2007-03-06 2008-09-12 Barry G. Arnason Methods and compositions involving polymeric immunoglobulin fusion proteins
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
MX2016015457A (es) * 2014-05-28 2017-06-30 Nono Inc Sal de cloruro de tat-nr2b9c.
AU2017253549B2 (en) * 2016-04-21 2021-01-21 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
JP7382310B2 (ja) * 2017-09-06 2023-11-16 カリフォルニア インスティチュート オブ テクノロジー シグナリング及び抗原提示の２機能性レセプター（ｓａｂｒ）

Also Published As

Publication number Publication date
HRP20200722T1 (hr) 2020-10-16
EP2172212A3 (en) 2010-04-14
KR102392070B1 (ko) 2022-04-29
EP3120870B1 (en) 2020-04-01
DK2172211T3 (en) 2015-02-16
HRP20170115T1 (hr) 2017-03-24
US10227381B2 (en) 2019-03-12
US20160376314A1 (en) 2016-12-29
TR201900852T4 (tr) 2019-02-21
US10047123B2 (en) 2018-08-14
EP2172211A1 (en) 2010-04-07
US20160355550A1 (en) 2016-12-08
PL3111952T3 (pl) 2019-04-30
EP3132801A1 (en) 2017-02-22
CN102170901A (zh) 2011-08-31
EP3111952A1 (en) 2017-01-04
HRP20201025T8 (hr) 2022-01-07
HRP20201015T1 (hr) 2020-10-16
CA2739384C (en) 2017-05-02
HRP20150223T1 (hr) 2015-06-05
HUE050428T2 (hu) 2020-12-28
EA201100586A1 (ru) 2011-10-31
HRP20161504T1 (hr) 2016-12-30
CY1123526T1 (el) 2022-03-24
EP3069728A1 (en) 2016-09-21
ES2710608T3 (es) 2019-04-26
US10919931B2 (en) 2021-02-16
AU2009300088B2 (en) 2014-09-04
HRP20182151T1 (hr) 2019-02-08
CA2936920C (en) 2019-12-03
DK2172212T3 (da) 2016-12-19
CA2936887C (en) 2019-11-12
PT3106175T (pt) 2020-07-01
RS58229B1 (sr) 2019-03-29
RS58443B1 (sr) 2019-04-30
EP3111952B1 (en) 2018-10-31
HRP20190202T1 (hr) 2019-03-22
EP3106175B1 (en) 2020-04-01
DK3120870T3 (da) 2020-06-22
PL3132801T3 (pl) 2020-06-15
DK3120869T3 (da) 2020-08-10
PT3124043T (pt) 2020-05-12
NZ603016A (en) 2014-05-30
LT3069728T (lt) 2019-02-11
EP2341927B1 (en) 2016-05-04
US20130004456A1 (en) 2013-01-03
HUE031030T2 (en) 2017-06-28
EP3069728B1 (en) 2018-11-14
SI3069728T1 (sl) 2019-03-29
RS60385B1 (sr) 2020-07-31
CY1121098T1 (el) 2019-12-11
SI3106175T1 (sl) 2020-08-31
JP6297632B2 (ja) 2018-03-20
EP3106175A1 (en) 2016-12-21
DK3069728T3 (en) 2019-02-25
EP2172212A2 (en) 2010-04-07
PT3132801T (pt) 2020-02-04
CA2936920A1 (en) 2010-04-08
WO2010037514A2 (en) 2010-04-08
US8119139B2 (en) 2012-02-21
JP2017000148A (ja) 2017-01-05
PL3120870T3 (pl) 2020-07-27
CA2936870C (en) 2019-11-26
NZ591882A (en) 2012-12-21
CN102170900B (zh) 2016-10-26
JP2017018102A (ja) 2017-01-26
JP5883476B2 (ja) 2016-03-15
US20130309193A1 (en) 2013-11-21
US20150125478A1 (en) 2015-05-07
KR102133402B1 (ko) 2020-07-14
US11136352B2 (en) 2021-10-05
CY1122913T1 (el) 2021-10-29
MX2011003540A (es) 2011-06-20
HRP20200110T1 (hr) 2020-05-15
RS60386B1 (sr) 2020-07-31
PT2331118T (pt) 2017-02-06
MX338294B (es) 2016-04-11
EP3120869A1 (en) 2017-01-25
CN102170901B (zh) 2015-01-07
US8653035B2 (en) 2014-02-18
CY1121258T1 (el) 2020-05-29
LT3132801T (lt) 2020-02-10
HUE049366T2 (hu) 2020-09-28
ES2819244T3 (es) 2021-04-15
LT3106175T (lt) 2020-08-10
ES2584245T3 (es) 2016-09-26
PL2172212T3 (pl) 2017-04-28
CN102170900A (zh) 2011-08-31
US20210238227A1 (en) 2021-08-05
US20160376313A1 (en) 2016-12-29
HRP20201228T1 (hr) 2021-02-05
ES2612466T3 (es) 2017-05-17
KR101687840B1 (ko) 2016-12-19
SI3120868T1 (sl) 2020-08-31
CA2936870A1 (en) 2010-04-08
CA2936924A1 (en) 2010-04-08
EP3124043A1 (en) 2017-02-01
HRP20160915T1 (hr) 2016-10-07
ES2804723T3 (es) 2021-02-09
SI3111952T1 (sl) 2019-01-31
JP2016047825A (ja) 2016-04-07
US20120141517A1 (en) 2012-06-07
HK1159526A1 (zh) 2012-08-03
KR101883426B1 (ko) 2018-07-31
CY1123089T1 (el) 2021-10-29
BRPI0920791B8 (pt) 2022-02-15
JP6294913B2 (ja) 2018-03-14
RS55531B1 (sr) 2017-05-31
SI3120870T1 (sl) 2020-08-31
PL2341927T3 (pl) 2016-11-30
JP5753783B2 (ja) 2015-07-22
EP3132801B1 (en) 2019-10-30
LT3120868T (lt) 2020-08-10
UA110599C2 (uk) 2016-01-25
EP3120869B1 (en) 2020-07-22
KR20110082155A (ko) 2011-07-18
JP2017029135A (ja) 2017-02-09
RS60381B1 (sr) 2020-07-31
US8318677B2 (en) 2012-11-27
US20160376316A1 (en) 2016-12-29
EP3120868A1 (en) 2017-01-25
BRPI0920791B1 (pt) 2022-01-18
SI2331118T1 (sl) 2017-01-31
DK3132801T3 (da) 2020-02-10
JP2017018101A (ja) 2017-01-26
US20100158931A1 (en) 2010-06-24
CA2936982A1 (en) 2010-04-08
US20190010190A1 (en) 2019-01-10
HUE029360T2 (en) 2017-02-28
EA023013B1 (ru) 2016-04-29
US10046037B2 (en) 2018-08-14
KR101756488B1 (ko) 2017-07-11
PT3111952T (pt) 2019-02-05
SI3120869T1 (sl) 2020-10-30
TR201900809T4 (tr) 2019-02-21
WO2010037513A1 (en) 2010-04-08
CY1123098T1 (el) 2021-10-29
RS53782B1 (en) 2015-06-30
NZ591855A (en) 2012-11-30
DK3111952T3 (en) 2019-01-28
AU2009300087B2 (en) 2014-09-04
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
NZ624533A (en) 2015-09-25
DK3106175T3 (da) 2020-06-22
JP2012504563A (ja) 2012-02-23
BRPI0920759A2 (pt) 2016-03-08
JP2012504393A (ja) 2012-02-23
US8895514B2 (en) 2014-11-25
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
PL2172211T3 (pl) 2015-05-29
JP6367266B2 (ja) 2018-08-01
EA201401104A1 (ru) 2015-05-29
AU2009300087A1 (en) 2010-04-08
PL3120868T3 (pl) 2020-08-24
US10941181B2 (en) 2021-03-09
CA2936869C (en) 2019-08-06
JP2016145210A (ja) 2016-08-12
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
ES2536465T3 (es) 2015-05-25
HUE030296T2 (en) 2017-04-28
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
ES2607460T3 (es) 2017-03-31
US8961985B2 (en) 2015-02-24
JP6150859B2 (ja) 2017-06-21
US20170326217A1 (en) 2017-11-16
EA032437B1 (ru) 2019-05-31
PT2172211E (pt) 2015-03-09
US9993540B2 (en) 2018-06-12
CY1118702T1 (el) 2017-07-12
HUE051030T2 (hu) 2021-01-28
JP6294914B2 (ja) 2018-03-14
CN106986919A (zh) 2017-07-28
JP2014239681A (ja) 2014-12-25
LT2331118T (lt) 2016-12-27
PT2341927T (pt) 2016-08-02
HUE042115T2 (hu) 2019-06-28
JP2017023136A (ja) 2017-02-02
DK2331118T3 (da) 2017-01-09
EP2331118A1 (en) 2011-06-15
CY1123113T1 (el) 2021-10-29
PL3124043T3 (pl) 2020-07-27
CA2739387C (en) 2019-10-29
JP5855940B2 (ja) 2016-02-09
CA2936887A1 (en) 2010-04-08
WO2010037514A3 (en) 2010-06-03
LT2172212T (lt) 2016-11-10
US20210253637A1 (en) 2021-08-19
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
PT3120868T (pt) 2020-07-16
HUE047365T2 (hu) 2020-04-28
CA2739384A1 (en) 2010-04-08
HK1161106A1 (en) 2012-08-24
DK3124043T3 (da) 2020-05-04
RS55043B1 (sr) 2016-12-30
CY1116302T1 (el) 2017-02-08
HRP20150223T8 (hr) 2015-07-03
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
LT3120869T (lt) 2020-11-10
US11208434B2 (en) 2021-12-28
CA2739387A1 (en) 2010-04-08
SI3132801T1 (sl) 2020-03-31
ES2708654T3 (es) 2019-04-10
EP2341927A2 (en) 2011-07-13
EP2172212B1 (en) 2016-10-05
EP3120868B1 (en) 2020-04-08
EP3124043B1 (en) 2020-04-29
US20210347822A1 (en) 2021-11-11
CA2936868A1 (en) 2010-04-08
LT3111952T (lt) 2018-12-27
CY1122677T1 (el) 2021-03-12
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
EP2172211B1 (en) 2014-12-03
JP6214066B2 (ja) 2017-10-18
HUE049364T2 (hu) 2020-09-28
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
DK2341927T3 (en) 2016-08-15
HUE041446T2 (hu) 2019-05-28
SI2172212T1 (sl) 2016-12-30
PT2172212T (pt) 2016-12-22
PL2331118T3 (pl) 2017-05-31
BRPI0920791A2 (pt) 2019-12-10
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
SI3124043T1 (sl) 2020-07-31
ES2770090T3 (es) 2020-06-30
RS55543B1 (sr) 2017-05-31
KR20180088494A (ko) 2018-08-03
US20210261614A1 (en) 2021-08-26
ES2802227T3 (es) 2021-01-18
PT3120869T (pt) 2020-09-22
MX2011003539A (es) 2011-06-20
US10906936B2 (en) 2021-02-02
US20160376317A1 (en) 2016-12-29
DK3120868T3 (da) 2020-06-22
KR20200085381A (ko) 2020-07-14
EP2331118B1 (en) 2016-10-26
KR20110074894A (ko) 2011-07-04
HUE049367T2 (hu) 2020-09-28
UA103202C2 (ru) 2013-09-25
PL3106175T3 (pl) 2020-08-24
RS60338B1 (sr) 2020-07-31
CA2936869A1 (en) 2010-04-08
CA2936868C (en) 2019-10-22
CY1119744T1 (el) 2018-06-27
AU2009300088A1 (en) 2010-04-08
US20160376315A1 (en) 2016-12-29
HRP20201015T8 (hr) 2022-01-21
CA2936982C (en) 2019-12-03
PT3120870T (pt) 2020-07-01
CA2936924C (en) 2019-07-16
EP3120870A1 (en) 2017-01-25
KR20160103558A (ko) 2016-09-01
KR20220058655A (ko) 2022-05-09
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
HRP20200988T1 (hr) 2020-10-16

Similar Documents

Publication Publication Date Title
ES2788129T8 (es) Inmunoterapia novedosa contra diversos tumores, entre ellos tumores cerebrales y neuronales
BRPI0813621A2 (pt) imunoterapia contra tumores neuronais e cerebrais